IQX Limited is a venture capital firm, and fund manager focuses on early stage investments in Australian biotech and life science companies and other registered intellectual property.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.13|
|52 Week High||AU$0.05|
|52 Week Low||AU$0.14|
|1 Month Change||0%|
|3 Month Change||n/a|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||-13.33%|
|Change since IPO||73.34%|
Recent News & Updates
|IQX||AU Capital Markets||AU Market|
Return vs Industry: Insufficient data to determine how IQX performed against the Australian Capital Markets industry.
Return vs Market: Insufficient data to determine how IQX performed against the Australian Market.
Stable Share Price: Insufficient data to determine IQX's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine IQX's volatility change over the past year.
About the Company
IQX Limited is a venture capital firm, and fund manager focuses on early stage investments in Australian biotech and life science companies and other registered intellectual property. It typically invest post discovery before pre-clinical. The firm is based in Sydney, Australia with additional offices in Sydney, Australia; New York, New York; and Shanghai, China.
iQX Fundamentals Summary
|IQX fundamental statistics|
Is IQX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IQX income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.054|
|Net Profit Margin||-603.35%|
How did IQX perform over the long term?See historical performance and comparison
Is iQX undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether iQX is trading at an attractive price based on the cash flow it is expected to produce in the future. But as iQX has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is iQX forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Diversified Financials industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iQX has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has iQX performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IQX is currently unprofitable.
Growing Profit Margin: IQX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IQX is unprofitable, and losses have increased over the past 5 years at a rate of 61.4% per year.
Accelerating Growth: Unable to compare IQX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IQX is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (12.8%).
Return on Equity
High ROE: IQX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is iQX's financial position?
Financial Position Analysis
Short Term Liabilities: IQX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: IQX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: IQX has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: IQX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IQX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IQX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 4% each year
What is iQX current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IQX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IQX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IQX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IQX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IQX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
George Syrmalis (55 yo)
Dr. George Syrmalis, M.D., Ph D., FACNP, MAAPP, has been Chief Executive Officer at FarmaForce Limited since November 24, 2015 and has been its Executive Director since November 24, 2015. He has been Chair...
CEO Compensation Analysis
Compensation vs Market: George's total compensation ($USD670.75K) is above average for companies of similar size in the Australian market ($USD302.38K).
Compensation vs Earnings: George's compensation has been consistent with company performance over the past year.
Experienced Board: IQX's board of directors are considered experienced (8.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
iQX Limited's employee growth, exchange listings and data sources
- Name: iQX Limited
- Ticker: IQX
- Exchange: NSX
- Founded: NaN
- Industry: Asset Management and Custody Banks
- Sector: Diversified Financials
- Market Cap: AU$56.182m
- Shares outstanding: 432.17m
- Website: https://www.iqxinvestments.com
- iQX Limited
- 85 Castlereagh Street
- Level 9
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/25 07:04|
|End of Day Share Price||2021/08/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.